Adrenocortical carcinoma research hub
5 indexed studies · 1 currently recruiting
- recruitingPhase II
A phase II trial of CY-101 in participants with adrenocortical cancer
This trial investigates a new drug called CY-101 for adrenocortical cancer that has spread. CY-101 works by attacking cancer cells and boosting the body's immune system. Researchers want to find the best dose, check its effectiveness, and understand any side effects.
United Kingdom · England - authorisedTherapeutic exploratory (Phase II)
Hyperthermic Intraperitoneal Chemotherapy and Regional Adrenalectomy in the management of Stage II & III Adrenocortical Carcinoma
This trial looks at a treatment for stage 2 and 3 adrenal gland cancer. Doctors remove the tumour and wash the inside of the abdomen with warm chemotherapy drugs. The main goal is to find out if this heated wash lowers the chance of cancer returning over three years.
Italy - active not recruiting
Preclinical Study Towards an Immunotherapy in Adrenocortical Carcinoma
This study is looking for new ways to treat a rare adrenal gland cancer called adrenocortical carcinoma (ACC). We want to find out if a special type of treatment, called immunotherapy, could help. This early-stage research aims to lay the groundwork for future treatments.
Germany - active not recruiting
Evaluation of Side Effects of Mitotane
This study looks at the side effects of a medicine called mitotane, used for a rare cancer called adrenocortical carcinoma. Doctors want to understand better what happens when people take this medicine.
Germany - authorisedTherapeutic exploratory (Phase II)
PROSPECTIVE, PHASE II STUDY TO EVALUATE THE EFFICACY OF ADDITION OF PROGESTERONE TO STANDARD CHEMOTHERAPY ACCORDING TO EDP SCHEME PLUS MITOTANE IN PATIENTS WITH ADVANCED ADRENAL CORTICAL CARCINOMA - PESETA TRIAL
This study is looking at new ways to treat advanced adrenal cancer. It's comparing standard chemotherapy with a combination that includes progesterone and another drug called mitotane, to see if the new combination works better at shrinking tumours.
Italy